Skip to main content
Top
Published in: Journal of Translational Medicine 1/2021

Open Access 01-12-2021 | Research

Establishment and validation of in-house cryopreserved CAR/TCR-T cell flow cytometry quality control

Authors: Yihua Cai, Michaela Prochazkova, Chunjie Jiang, Hannah W. Song, Jianjian Jin, Larry Moses, Nikolaos Gkitsas, Robert P. Somerville, Steven L. Highfill, Sandhya Panch, David F. Stroncek, Ping Jin

Published in: Journal of Translational Medicine | Issue 1/2021

Login to get access

Abstract

Background

Chimeric antigen receptor (CAR) or T-cell receptor (TCR) engineered T-cell therapy has recently emerged as a promising adoptive immunotherapy approach for the treatment of hematologic malignancies and solid tumors. Multiparametric flow cytometry-based assays play a critical role in monitoring cellular manufacturing steps. Since manufacturing CAR/TCR T-cell products must be in compliance with current good manufacturing practices (cGMP), a standard or quality control for flow cytometry assays should be used to ensure the accuracy of flow cytometry results, but none is currently commercially available. Therefore, we established a procedure to generate an in-house cryopreserved CAR/TCR T-cell products for use as a flow cytometry quality control and validated their use.

Methods

Two CAR T-cell products: CD19/CD22 bispecific CAR T-cells and FGFR4 CAR T-cells and one TCR-engineered T-cell product: KK-LC-1 TCR T-cells were manufactured in Center for Cellular Engineering (CCE), NIH Clinical Center. The products were divided in aliquots, cryopreserved and stored in the liquid nitrogen. The cryopreserved flow cytometry quality controls were tested in flow cytometry assays which measured post-thaw viability, CD3, CD4 and CD8 frequencies as well as the transduction efficiency and vector identity. The long-term stability and shelf-life of cryopreserved quality control cells were evaluated. In addition, the sensitivity as well as the precision assay were also assessed on the cryopreserved quality control cells.

Results

After thawing, the viability of the cryopreserved CAR/TCR T-cell controls was found to be greater than 50%. The expression of transduction efficiency and vector identity markers by the cryopreserved control cells were stable for at least 1 year; with post-thaw values falling within ± 20% range of the values measured at time of cryopreservation. After thawing and storage at room temperature, the stability of these cryopreserved cells lasted at least 6 h. In addition, our cryopreserved CAR/TCR-T cell quality controls showed a strong correlation between transduction efficiency expression and dilution factors. Furthermore, the results of flow cytometric analysis of the cryopreserved cells among different laboratory technicians and different flow cytometry instruments were comparable, highlighting the reproducibility and reliability of these quality control cells.

Conclusion

We developed and validated a feasible and reliable procedure to establish a bank of cryopreserved CAR/TCR T-cells for use as flow cytometry quality controls, which can serve as a quality control standard for in-process and lot-release testing of CAR/TCR T-cell products.
Appendix
Available only for authorised users
Literature
1.
go back to reference June CH, et al. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–5.CrossRef June CH, et al. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–5.CrossRef
2.
go back to reference Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21(3):145–61.CrossRef Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21(3):145–61.CrossRef
3.
go back to reference O’Leary MC, et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res. 2019;25(4):1142–6.CrossRef O’Leary MC, et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res. 2019;25(4):1142–6.CrossRef
4.
go back to reference Neelapu SS, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44.CrossRef Neelapu SS, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44.CrossRef
5.
go back to reference Gee AP. GMP CAR-T cell production. Best Pract Res Clin Haematol. 2018;31(2):126–34.CrossRef Gee AP. GMP CAR-T cell production. Best Pract Res Clin Haematol. 2018;31(2):126–34.CrossRef
6.
go back to reference Campbell JDM, Fraser AR. Flow cytometric assays for identity, safety and potency of cellular therapies. Cytometry B Clin Cytom. 2018;94(5):569–79.CrossRef Campbell JDM, Fraser AR. Flow cytometric assays for identity, safety and potency of cellular therapies. Cytometry B Clin Cytom. 2018;94(5):569–79.CrossRef
7.
go back to reference Reddy OL, Stroncek DF, Panch SR. Improving CAR T cell therapy by optimizing critical quality attributes. Semin Hematol. 2020;57(2):33–8.CrossRef Reddy OL, Stroncek DF, Panch SR. Improving CAR T cell therapy by optimizing critical quality attributes. Semin Hematol. 2020;57(2):33–8.CrossRef
8.
go back to reference Demaret J, et al. Monitoring CAR T-cells using flow cytometry. Cytometry B Clin Cytom. 2021;100(2):218–24.CrossRef Demaret J, et al. Monitoring CAR T-cells using flow cytometry. Cytometry B Clin Cytom. 2021;100(2):218–24.CrossRef
9.
go back to reference Sarikonda G, et al. Best practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell analyses. Cytometry B Clin Cytom. 2021;100(1):79–91.CrossRef Sarikonda G, et al. Best practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell analyses. Cytometry B Clin Cytom. 2021;100(1):79–91.CrossRef
10.
go back to reference Vormittag P, et al. A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol. 2018;53:164–81.CrossRef Vormittag P, et al. A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol. 2018;53:164–81.CrossRef
11.
go back to reference Lu A, et al. Application of droplet digital PCR for the detection of vector copy number in clinical CAR/TCR T cell products. J Transl Med. 2020;18(1):191.CrossRef Lu A, et al. Application of droplet digital PCR for the detection of vector copy number in clinical CAR/TCR T cell products. J Transl Med. 2020;18(1):191.CrossRef
12.
go back to reference Wang L, Hoffman RA. Standardization, calibration, and control in flow cytometry. Curr Protoc Cytom. 2017;79:1.3.1-1.3.27. Wang L, Hoffman RA. Standardization, calibration, and control in flow cytometry. Curr Protoc Cytom. 2017;79:1.3.1-1.3.27.
13.
go back to reference Owens MA, et al. Validation and quality control of immunophenotyping in clinical flow cytometry. J Immunol Methods. 2000;243(1–2):33–50.CrossRef Owens MA, et al. Validation and quality control of immunophenotyping in clinical flow cytometry. J Immunol Methods. 2000;243(1–2):33–50.CrossRef
14.
go back to reference FDA, U.S., Bioanalytical method validation guidance for industry, C.f.D.E.a.R.C.f.V. Medicine, Editor. 2018. FDA, U.S., Bioanalytical method validation guidance for industry, C.f.D.E.a.R.C.f.V. Medicine, Editor. 2018.
15.
go back to reference Nicholson JK, Hubbard M, Dawson CD. Evaluation of stabilized whole blood control materials for lymphocyte immunophenotyping. Cytometry. 1999;38(6):268–73.CrossRef Nicholson JK, Hubbard M, Dawson CD. Evaluation of stabilized whole blood control materials for lymphocyte immunophenotyping. Cytometry. 1999;38(6):268–73.CrossRef
16.
go back to reference Zheng Z, Chinnasamy N, Morgan RA. Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry. J Transl Med. 2012;10:29.CrossRef Zheng Z, Chinnasamy N, Morgan RA. Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry. J Transl Med. 2012;10:29.CrossRef
17.
go back to reference Kapoore RV, et al. Effects of cryopreservation on viability and functional stability of an industrially relevant alga. Sci Rep. 2019;9(1):2093.CrossRef Kapoore RV, et al. Effects of cryopreservation on viability and functional stability of an industrially relevant alga. Sci Rep. 2019;9(1):2093.CrossRef
Metadata
Title
Establishment and validation of in-house cryopreserved CAR/TCR-T cell flow cytometry quality control
Authors
Yihua Cai
Michaela Prochazkova
Chunjie Jiang
Hannah W. Song
Jianjian Jin
Larry Moses
Nikolaos Gkitsas
Robert P. Somerville
Steven L. Highfill
Sandhya Panch
David F. Stroncek
Ping Jin
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2021
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-021-03193-7

Other articles of this Issue 1/2021

Journal of Translational Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine